Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    A new version of the clinical trial record was added, documenting updates to its recruitment and study status.
    Difference
    0.0%
    Check dated 2026-11-08T04:53:46.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.0%
    Check dated 2026-11-01T01:58:06.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    0.3%
    Check dated 2026-10-25T02:02:26.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2.
    Difference
    0.0%
    Check dated 2026-10-18T01:52:55.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now identifies the site as revision v3.7.1 instead of v3.7.0.
    Difference
    0.0%
    Check dated 2026-10-11T02:20:52.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The history now shows a new revision entry labeled v3.7.0. The previous entry v3.6.6 has been removed.
    Difference
    0.0%
    Check dated 2026-09-20T00:58:10.000Z thumbnail image

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.